PMPRB Summary of VCUs & Orders - 2009

Click on medicine to view details of VCU

Date of Approval Medicine Patentee % Above Guidelines Price Reduction1 Excess Revenues2 Payments Patent Status
VCUs
Oct. 16, 2009 Andriol Schering-Plough Canada Inc. See VCU See VCU $3,392,652.63 $348,605.86 Expiration: Mar. 27, 2020
Oct. 16, 2009 Neulasta1 Amgen Canada Inc. See VCU See VCU $6,730,120.32 $6,730,120.32 Expiration:Jul. 31, 2024
Oct. 5, 2009 Brevibloc Baxter Corporation See VCU 2009 MNE: $1.0086 $212,440.76 $212,440.76 Expiration: Jan. 2, 2022
April 24, 2009 Concerta2 Janssen-Ortho Inc. See VCU See VCU $1,464,441.58 $1,464,441.58 Expiration: Nov. 1, 2017
April 23, 2009 Eligard sanofi-aventis Canada Inc. See VCU See VCU $13,127,953.14 $13,127,953.14 Expiration: Sept. 1, 2021
Mar. 4, 2009 Suprax sanofi-aventis Canada Inc. See VCU 2009 MNE: $3.4304 $97,900.30 $97,900.30 Expiration: Nov. 1, 2011
February 23, 2009 Vepesid Bristol-Myers Squibb Canada Co. See VCU Yes $53,161.48 $53,161.48 Expiration Oct 1, 2014
February 19, 2009 Strattera3 Eli Lilly Canada Inc. See VCU Yes $15,326,066.49 $15,326,066.49 Expiration Sept 1, 2018
ORDER

1 The Board issued an Order - PMPRB-09-D1-NEULASTA - on October 21, 2009, concluding the proceeding in the matter of Amgen Canada Inc. and the patented medicine Neulasta, initiated with the issuance of a Notice of Hearing on March 16, 2009.

2 The Board issued an Order – PMPRB-06-D1-CONCERTA - on April 24, 2009, concluding the proceeding in the matter of Janssen-Ortho Inc. and the patented medicine Concerta initiated with the issuance of a Notice of Hearing on July 24, 2006.

3 The Board issued an Order – PMPRB-06-D1-STRATTERA - on February 19, 2009, concluding the proceeding in the matter of Eli Lilly Canada Inc. and the patented medicine Strattera initiated with the issuance of a Notice of Hearing on December 15, 2006.

Date modified: